Eli Lilly and Company
LLY
Below: live stock price for Eli Lilly and Company (LLY), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Eli Lilly and Company (LLY) trades at 1,182.62 USD on cryptosrank.
- Prev close
- $1,179.27
- Volume (24h)
- $1.47B
- Market cap
- $1.05T
- Currency
- USD
Score
Insufficient data
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 1,180.39 -0.19%
- +20 bars
- 1,177.33 -0.45%
- +60 bars
- 1,176.15 -0.55%
- +120 bars
- 1,176.1 -0.55%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0298 USD.
Interpretation
Price sits in the middle of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 34.2%
- Max drawdown
- -23.3%
- Below period high
- -8.5%
- Best day
- +10.33%
- Worst day
- -7.79%
- Up days
- 50%
- Current streak
- 2 up
- Typical day swing
- 2.9%
- Volume vs average
- -23%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 1,292.65 high → 1,109.15 low · 60 bars
- ResistanceFib +161.8% extensionnot reached1,589.55 USD+34.41% from current
- ResistanceFib +100% extensionnot reached1,476.15 USD+24.82% from current
- ResistanceFib +61.8% extensionnot reached1,406.05 USD+18.89% from current
- ResistanceFib +27.2% extensionnot reached1,342.56 USD+13.52% from current
- ResistanceFib 23.6% retracementtested 5×1,249.34 USD+5.64% from current
- ResistanceFib 38.2% retracementtested 9×1,222.55 USD+3.38% from current
- ResistanceFib 50% midpointtested 10×1,200.9 USD+1.55% from current
- Current1,182.62 USD
- SupportFib 61.8% retracementNearesttested 23×1,179.25 USD-0.29% from current
- SupportFib 78.6% retracementtested 22×1,148.42 USD-2.89% from current
- SupportFib −27.2% extensionnot reached1,059.24 USD-10.43% from current
- SupportFib −61.8% extensionnot reached995.747 USD-15.80% from current
- SupportFib −100% extensionnot reached925.65 USD-21.73% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Recent news
- Sector Update: Healthcare Stocks Rise Late AfternoonMT Newswires56m ago
- 4 Healthcare Stocks Worth Owning for the Next DecadeMotley Fool5h ago
- Eli Lilly Likely to Post Strong Volume Growth in Q3, RBC SaysMT Newswires5h ago
- Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks5h ago
- 2 S&P 500 Stocks to Own for Decades and 1 We Find RiskyStockStory5h ago
- Eli Lilly (LLY) Phase 3b Win Connects Psoriasis And Obesity TreatmentSimply Wall St.5h ago
- Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?Zacks6h ago
- Lilly is fighting a black market for its new obesity drug even before it launchesPharma Voice7h ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,462 USD-1.20%
- 7203.TToyota Motor Corporation2,910.5 USD+0.29%
- 9984.TSoftBank Group Corp.5,803 USD-3.92%
- 6758.TSony Group Corporation3,814 USD+2.91%
- 6861.TKeyence Corporation80,540 USD+0.68%
- NVDANVIDIA Corporation226.32 USD-1.29%
- AAPLApple Inc.340.97 USD+1.29%
- GOOGLAlphabet Inc.352.72 USD+0.30%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.